Established development process
Using our novel drug delivery system we have established the entire process of development and functional testing of promising therapeutic targets and successfully completed it for two targets. These two RNA-interference-based oncological clinical candidates show a superior tumor reduction and elimination of metastases in human cancer xenograft models. Several other promising candidates are part of Soluventis pipeline.
Together with the new drug delivery platform Soluventis has a portfolio of oncologic siRNAs which significantly improve tumor reduction and elimination of metastases in comparison to standard chemotherapeutic agents in xenograft studies.
Difficult oncological indication: Pancreatic cancer
Pancreatic cancer has the highest mortality rate and the lowest overall survival of all cancers (20% at 1 year; 4% at 5 years). It is the fourth leading cause of cancer death and shows insensitivity to most therapies including chemotherapy, radiotherapy and immunotherapy. It is characterized by a remarkable resistance to cell stress induced by chemotherapy and radiotherapy. Due to the predominance of fibrotic stroma, creating a barrier against drug delivery and immune cell infiltration and its poor vascularization it is very difficult to attack. Until now, Gemcitabine remains the standard treatment but with poor life prolongation.
The first therapeutic concept that eliminates pancreas cancer metastases
Human pancreatic cancer metastases were detected in an external xenograft study.
Animals treated with vehicle only, a Nanocarrier + siRNA control, the conventional chemotherapeutic agent Gemcitabine at highest dose and two novel siRNA therapeutics. The Soluventis Nanocarrier-based therapy with two new siRNAs is more efficient than the standard chemotherapeutic agent Gemcitabine.